engage:BDR projects $1.5M cash outflow boost

Published 01-MAY-2019 11:58 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Engage:BDR (ASX:EN1) has provided its report for the quarter ended March 31, 2019.

The quarterly update reflected highly encouraging results for the emerging programmatic tech player, with results including:

  • Net cash from operations improved by A$3.9M (or 69% year-on-year)
  • Cash outflow decreased by A$4.9M (or 57% yoy)
  • Cash balance increased 253%
  • Available financing facilities increased to A$13.5M
  • A$1.5M improvement in cash outflow projected for Q2 2019
  • Q2 expected to deliver positive net cash, targeting cash balance growth
  • April 2019 receipts were A$1.33M (representing 68% of total receipts for Q1)
  • Average daily revenue in April up nearly 200% of Q1
  • April 2019 net cash from operating activities was A$41.4k
  • Run-rate to monthly profitability near, potentially before mid-year
  • Average daily gap to profitability currently A$2-3k gross profit

Daily revenues

Average daily revenue is up nearly 200% in the month of April compared to Q1. EN1 has pointed to its recent deployment of A$1.35 million to activate incremental publishers for its programmatic advertising business. In addition, EN1 is continuing new client onboardings to its IconicReach platforms, with the company expecting both processes to deliver increasing revenue streams throughout the year.

Future revenue

Companies involved in the advertising industry typically experience their lightest revenues during the first and second quarters of the year. EN1’s revenue increased sizeably when it announced preliminary results of its incremental publisher activations on March 18, just 13 days prior to the close of the quarter.

The majority of this incremental revenue growth was attributed to April 2019 and beyond. EN1 initially deployed A$1.1 million to publishers in February and March, which was expected to yield revenue for the balance of the year (which continues to exceed EN1’s expectations).

In addition, another A$250,000 was deployed to publishers before the end of March, for a total result of A$1.35 million, which will produce strong results in Q2.

Profitability

As previously mentioned, the company informed the market that it is close to achieving monthly profitability. EN1 expects to achieve its first accrual-based profitable month around the half-year mark (excluding non-cash expenses).

This estimation is based on the consistency of revenues and margins achieved by the company over the past 45 days, which see it around A$2000-$3000 gross profit away from monthly profitability as current.

At the time of writing, EN1 was up 4.5%, trading at 4.6 cents.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X